Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness

Eric Hollander, Andrea Allen, Jee Kwon, Bonnie Aronowitz, James Schmeidler, Cheryl Wong, Daphne Simeon

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Background: Body dysmorphic disorder (preoccupation with an imagined or slight defect in appearance) is a common and disabling disorder associated with high rates of delusional symptoms and suicide attempts. Although preliminary studies suggest that serotonin reuptake inhibitors may be effective for body dysmorphic disorder, to date no controlled treatment studies have been published. Methods: Forty patients were enrolled and 29 were randomized into a 16-week, double-blind, crossover-design study of clomipramine, a potent serotonin reuptake inhibitor, and active control desipramine, a selective norepinephrine reuptake inhibitor. Outcome measures included specific ratings of body dysmorphic disorder severity, delusionality, and functional impairment. Results: Clomipramine was superior to desipramine in the acute treatment of body dysmorphic disorder symptoms as measured by assessment of patients' obsessive preoccupation with perceived body defects, repetitive behaviors in response to this preoccupation, and global ratings of symptom severity. Treatment efficacy was independent of the presence or severity of comorbid diagnoses of obsessive-compulsive disorder, depression, or social phobia. Likewise, clomipramine was equally effective regardless of whether the patients had insight or held their dysmorphic misperception with delusional intensity. Clomipramine was also superior to desipramine in improving functional disability. Conclusions: Clomipramine is more effective than desipramine in the treatment of body dysmorphic disorder and is effective even among those patients who are delusional.

Original languageEnglish (US)
Pages (from-to)1033-1039
Number of pages7
JournalArchives of General Psychiatry
Volume56
Issue number11
DOIs
StatePublished - Nov 1999
Externally publishedYes

Fingerprint

Body Dysmorphic Disorders
Clomipramine
Desipramine
Serotonin Uptake Inhibitors
Cross-Over Studies
Obsessive-Compulsive Disorder
Suicide
Norepinephrine
Therapeutics
Outcome Assessment (Health Care)
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Clomipramine vs desipramine crossover trial in body dysmorphic disorder : Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. / Hollander, Eric; Allen, Andrea; Kwon, Jee; Aronowitz, Bonnie; Schmeidler, James; Wong, Cheryl; Simeon, Daphne.

In: Archives of General Psychiatry, Vol. 56, No. 11, 11.1999, p. 1033-1039.

Research output: Contribution to journalArticle

Hollander, Eric ; Allen, Andrea ; Kwon, Jee ; Aronowitz, Bonnie ; Schmeidler, James ; Wong, Cheryl ; Simeon, Daphne. / Clomipramine vs desipramine crossover trial in body dysmorphic disorder : Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. In: Archives of General Psychiatry. 1999 ; Vol. 56, No. 11. pp. 1033-1039.
@article{826849a801ba4ecf81e0f431d1bb8ea0,
title = "Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness",
abstract = "Background: Body dysmorphic disorder (preoccupation with an imagined or slight defect in appearance) is a common and disabling disorder associated with high rates of delusional symptoms and suicide attempts. Although preliminary studies suggest that serotonin reuptake inhibitors may be effective for body dysmorphic disorder, to date no controlled treatment studies have been published. Methods: Forty patients were enrolled and 29 were randomized into a 16-week, double-blind, crossover-design study of clomipramine, a potent serotonin reuptake inhibitor, and active control desipramine, a selective norepinephrine reuptake inhibitor. Outcome measures included specific ratings of body dysmorphic disorder severity, delusionality, and functional impairment. Results: Clomipramine was superior to desipramine in the acute treatment of body dysmorphic disorder symptoms as measured by assessment of patients' obsessive preoccupation with perceived body defects, repetitive behaviors in response to this preoccupation, and global ratings of symptom severity. Treatment efficacy was independent of the presence or severity of comorbid diagnoses of obsessive-compulsive disorder, depression, or social phobia. Likewise, clomipramine was equally effective regardless of whether the patients had insight or held their dysmorphic misperception with delusional intensity. Clomipramine was also superior to desipramine in improving functional disability. Conclusions: Clomipramine is more effective than desipramine in the treatment of body dysmorphic disorder and is effective even among those patients who are delusional.",
author = "Eric Hollander and Andrea Allen and Jee Kwon and Bonnie Aronowitz and James Schmeidler and Cheryl Wong and Daphne Simeon",
year = "1999",
month = "11",
doi = "10.1001/archpsyc.56.11.1033",
language = "English (US)",
volume = "56",
pages = "1033--1039",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Clomipramine vs desipramine crossover trial in body dysmorphic disorder

T2 - Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness

AU - Hollander, Eric

AU - Allen, Andrea

AU - Kwon, Jee

AU - Aronowitz, Bonnie

AU - Schmeidler, James

AU - Wong, Cheryl

AU - Simeon, Daphne

PY - 1999/11

Y1 - 1999/11

N2 - Background: Body dysmorphic disorder (preoccupation with an imagined or slight defect in appearance) is a common and disabling disorder associated with high rates of delusional symptoms and suicide attempts. Although preliminary studies suggest that serotonin reuptake inhibitors may be effective for body dysmorphic disorder, to date no controlled treatment studies have been published. Methods: Forty patients were enrolled and 29 were randomized into a 16-week, double-blind, crossover-design study of clomipramine, a potent serotonin reuptake inhibitor, and active control desipramine, a selective norepinephrine reuptake inhibitor. Outcome measures included specific ratings of body dysmorphic disorder severity, delusionality, and functional impairment. Results: Clomipramine was superior to desipramine in the acute treatment of body dysmorphic disorder symptoms as measured by assessment of patients' obsessive preoccupation with perceived body defects, repetitive behaviors in response to this preoccupation, and global ratings of symptom severity. Treatment efficacy was independent of the presence or severity of comorbid diagnoses of obsessive-compulsive disorder, depression, or social phobia. Likewise, clomipramine was equally effective regardless of whether the patients had insight or held their dysmorphic misperception with delusional intensity. Clomipramine was also superior to desipramine in improving functional disability. Conclusions: Clomipramine is more effective than desipramine in the treatment of body dysmorphic disorder and is effective even among those patients who are delusional.

AB - Background: Body dysmorphic disorder (preoccupation with an imagined or slight defect in appearance) is a common and disabling disorder associated with high rates of delusional symptoms and suicide attempts. Although preliminary studies suggest that serotonin reuptake inhibitors may be effective for body dysmorphic disorder, to date no controlled treatment studies have been published. Methods: Forty patients were enrolled and 29 were randomized into a 16-week, double-blind, crossover-design study of clomipramine, a potent serotonin reuptake inhibitor, and active control desipramine, a selective norepinephrine reuptake inhibitor. Outcome measures included specific ratings of body dysmorphic disorder severity, delusionality, and functional impairment. Results: Clomipramine was superior to desipramine in the acute treatment of body dysmorphic disorder symptoms as measured by assessment of patients' obsessive preoccupation with perceived body defects, repetitive behaviors in response to this preoccupation, and global ratings of symptom severity. Treatment efficacy was independent of the presence or severity of comorbid diagnoses of obsessive-compulsive disorder, depression, or social phobia. Likewise, clomipramine was equally effective regardless of whether the patients had insight or held their dysmorphic misperception with delusional intensity. Clomipramine was also superior to desipramine in improving functional disability. Conclusions: Clomipramine is more effective than desipramine in the treatment of body dysmorphic disorder and is effective even among those patients who are delusional.

UR - http://www.scopus.com/inward/record.url?scp=0032699839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032699839&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.56.11.1033

DO - 10.1001/archpsyc.56.11.1033

M3 - Article

C2 - 10565503

AN - SCOPUS:0032699839

VL - 56

SP - 1033

EP - 1039

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 11

ER -